Myles Minter
Stock Analyst at William Blair
(4.96)
# 109
Out of 4,592 analysts
566
Total ratings
60.5%
Success rate
34.9%
Average return
Main Sectors:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Reiterated: Buy | n/a | $166.71 | - | 32 | Jul 31, 2026 | |
| MRNA Moderna | Maintained: Hold | n/a | $56.15 | - | 28 | Jul 31, 2026 | |
| CTNM Contineum Therapeutics | Maintained: Buy | n/a | $14.83 | - | 9 | Jul 31, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | n/a | $203.37 | - | 17 | Jul 30, 2026 | |
| BIIB Biogen | Maintained: Buy | n/a | $205.52 | - | 31 | Jul 29, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | n/a | $51.65 | - | 51 | Jul 29, 2026 | |
| NMRA Neumora Therapeutics | Maintained: Buy | n/a | $1.52 | - | 15 | Jul 27, 2026 | |
| RAPP Rapport Therapeutics | Initiated Coverage: Buy | n/a | $41.32 | - | 1 | Jul 27, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | n/a | $3.43 | - | 11 | Jul 27, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | n/a | $80.16 | - | 9 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $475.86 | - | 32 | Jul 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.69 | - | 21 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.24905 | - | 11 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.78 | - | 19 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $859.28 | - | 19 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.74 | - | 17 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.23 | - | 25 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $106.59 | - | 20 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $218.45 | - | 63 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $13.51 | - | 11 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.30 | - | 13 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.28 | - | 11 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.87 | - | 13 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $27.05 | - | 13 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.25 | - | 10 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $81 | $63.18 | +27.66% | 14 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.53 | - | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.77 | - | 12 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.82 | - | 1 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.77 | n/a | 3 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.94 | n/a | 3 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $305.20 | n/a | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.97 | n/a | 15 | Dec 29, 2022 |
Neurocrine Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $166.71
Upside: -
Moderna
Jul 31, 2026
Maintained: Hold
Price Target: n/a
Current: $56.15
Upside: -
Contineum Therapeutics
Jul 31, 2026
Maintained: Buy
Price Target: n/a
Current: $14.83
Upside: -
Alnylam Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: n/a
Current: $203.37
Upside: -
Biogen
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $205.52
Upside: -
Ionis Pharmaceuticals
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $51.65
Upside: -
Neumora Therapeutics
Jul 27, 2026
Maintained: Buy
Price Target: n/a
Current: $1.52
Upside: -
Rapport Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $41.32
Upside: -
Camp4 Therapeutics
Jul 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.43
Upside: -
BridgeBio Pharma
Jul 22, 2026
Maintained: Buy
Price Target: n/a
Current: $80.16
Upside: -
Jul 7, 2026
Maintained: Buy
Price Target: n/a
Current: $475.86
Upside: -
Jul 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.69
Upside: -
Jun 30, 2026
Maintained: Hold
Price Target: n/a
Current: $0.24905
Upside: -
Jun 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.78
Upside: -
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $859.28
Upside: -
Jun 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.74
Upside: -
Jun 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.23
Upside: -
Jun 10, 2026
Maintained: Buy
Price Target: n/a
Current: $106.59
Upside: -
Jun 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $218.45
Upside: -
May 28, 2026
Reiterated: Hold
Price Target: n/a
Current: $13.51
Upside: -
May 22, 2026
Maintained: Buy
Price Target: n/a
Current: $23.30
Upside: -
May 18, 2026
Maintained: Buy
Price Target: n/a
Current: $10.28
Upside: -
May 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.87
Upside: -
May 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $27.05
Upside: -
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $2.25
Upside: -
May 8, 2026
Reiterated: Buy
Price Target: $81
Current: $63.18
Upside: +27.66%
May 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.53
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $6.77
Upside: -
Mar 31, 2026
Maintained: Buy
Price Target: n/a
Current: $12.82
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $3.77
Upside: n/a
Sep 28, 2023
Maintained: Buy
Price Target: n/a
Current: $3.94
Upside: n/a
Mar 3, 2023
Downgraded: Hold
Price Target: n/a
Current: $305.20
Upside: n/a
Dec 29, 2022
Rated: Hold
Price Target: n/a
Current: $3.97
Upside: n/a